| P50 | author | Eithan Galun | Q47008783 |
| P2093 | author name string | Rami Eliakim | |
| | Talia Golan | |
| | Eylon Yavin | |
| | Hilla Giladi | |
| | Ludmila Rivkin | |
| | Rinat Abramovitch | |
| | Ayala Hubert | |
| | Yael Kopelman | |
| | Abraham J Domb | |
| | Abed Khalaileh | |
| | Eran Goldin | |
| | Adva Shemi | |
| | Yael Hants | |
| | Amotz Shemi | |
| | Elad Horwitz | |
| | Ariel Orbach | |
| | Maor Lahav | |
| | Sagit Arbel-Alon | |
| | Zivia Brunschwig | |
| | Elina Zorde Khvalevsky | |
| | Alina Simerzin | |
| | Alan Dancour | |
| | Itzhak Haim Rachmut | |
| | Racheli Gabai | |
| P2860 | cites work | Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling | Q24293500 |
| | Genetic and epigenetic alterations in pancreatic carcinogenesis | Q24598655 |
| | Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 |
| | Pancreatic cancer | Q29616288 |
| | In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro | Q29617927 |
| | Pancreatic cancer. | Q30490247 |
| | K-ras as a target for cancer therapy | Q36248002 |
| | Molecular genetics of pancreatic intraepithelial neoplasia | Q36829524 |
| | Oncogene addiction: setting the stage for molecularly targeted cancer therapy | Q37031755 |
| | Drug delivery systems with modified release for systemic and biophase bioavailability | Q38026125 |
| | Biopolymer nanoparticle production for controlled release of biopharmaceuticals | Q38072083 |
| | Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer | Q38073775 |
| | Biomaterial-based drug delivery systems for the controlled release of neurotrophic factors. | Q38079443 |
| | A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival | Q39845869 |
| | Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion | Q40014102 |
| | K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment | Q40134965 |
| | Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy | Q40392798 |
| | Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses. | Q40977239 |
| | Testing transgenic regulatory elements through live mouse imaging | Q45869949 |
| | Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. | Q52827026 |
| | Molecular biology of pancreatic cancer | Q81973822 |
| | In vitro cell migration and invasion assays | Q84914731 |
| P433 | issue | 51 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 20723-20728 | |
| P577 | publication date | 2013-12-02 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Mutant KRAS is a druggable target for pancreatic cancer | |
| P478 | volume | 110 | |